Abiraterone – USA

Abiraterone – USA

IPR decision (January 17, 2018):

AIA Review
Filing Date
Institution Date
Petitioner
Patent No.
Status
IPR2016-01317
IPR2016-00286
IPR2016-01582
IPR2017-00853
IPR2016-01332
12/04/2015
06/29/2016
06/30/2016
08/10/2016
02/08/2017
05/31/2016
09/19/2016
01/10/2017
01/19/2017
04/12/2017
Amerigen
Argentum
Mylan
Wockhardt
Actavis
US 8,822,438
Final Written Decision
(claims 1–20 are unpatentable)
PTAB concluded that Petitioner has demonstrated that the preponderance of the evidence of record supports that it would have been obvious to the ordinary artisan at the time of invention to combine Gerberwith O’Donnellor Barrie and/or Sartor, with a reasonable expectation of success. The secondary considerations of nonobviousness raised by Patent Owner are neutral or not in favor of the patentability of the challenged claims, and do not outweigh the other Graham factors in obviousness analysis.

US 8,822,438 (expiring on Aug 24, 2027) claims a method for the treatment of a prostate cancer with abiraterone and prednisone.
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved